NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference

NovaBridge (Nasdaq: NBP) announced management will present at the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026.

Rhea-AI Summary

NovaBridge (Nasdaq: NBP) announced management will present at the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026. The company will appear in a fireside chat at 8:00 AM ET, and a webcast will be available on the company website for 90 days.

According to the company, the webcast link will be accessible via the News & Events page and the presentation runs within the conference held March 8-11, 2026.

Argus Mar 2 session

+5.18% close to close Open Argus

Details

News Market Reaction – NBP

In the Mar 2 session, NBP gained 5.18%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.2% in the session following this news. A strong positive reaction aligns with Nov...

Analysis

The stock moved +5.2% in the session following this news. A strong positive reaction aligns with NovaBridge’s pattern of constructive responses to visibility and pipeline updates, such as prior gains on insider buying and Phase 2 trial initiation. Participation in a major healthcare conference extends recent investor‑facing efforts and may have reinforced the story around givastomig, VIS‑101, and the broader platform. Investors would need to weigh how much of this exposure was already reflected in a stock trading 36.8% below its 52‑week high and below its 200‑day MA.

Key Figures

Conference dates: March 8–11, 2026 Presentation date: March 11, 2026 Presentation time: 8:00 AM ET +1 more

Conference dates

March 8–11, 2026

Leerink Partners Global Healthcare Conference

Presentation date

March 11, 2026

Fireside chat scheduled on conference Wednesday

Presentation time

8:00 AM ET

Scheduled time for NovaBridge fireside chat

Webcast availability

90 days

Replay hosted on NovaBridge website News & Events page

Historical Context

5 past events · Latest: Feb 19

5 events

1. Feb 19

   Leadership change

   24h Move

   +0.9%

   Appointment of Emmett T. Cunningham Jr. as Vice Chairman and R&D committee member.

2. Feb 17

   Clinical trial update

   24h Move

   +2.2%

   First patient dosed in global randomized Phase 2 givastomig gastric cancer study.

3. Jan 20

   Insider share purchases

   24h Move

   +5.1%

   Executive Chairman’s plan to buy up to $5,000,000 of ADSs in the open market.

4. Jan 06

   Clinical data update

   24h Move

   -11.2%

   Positive Phase 1b givastomig dose expansion data in 1L metastatic gastric cancer.

5. Dec 30

   Index inclusion & bell

   24h Move

   -1.7%

   Announcement of Nasdaq Opening Bell ceremony and inclusion in Nasdaq Biotech Index.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., March 02, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that NovaBridge’s management team will participate in the upcoming Leerink Partners 2026 Global Healthcare Conference being held on March 8-11, 2026.

Conference details are as follows:

Leerink Partners Global Healthcare Conference
Format: Fireside Chat
Date: Wednesday, March 11, 2026
Time: 8:00 AM ET
Webcast Link: Here

The webcast of the company presentation will be accessible on the News & Events page of the NovaBridge website for 90 days.

About NovaBridge

NovaBridge is a global biotechnology platform company committed to accelerating access to innovative medicines. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. By bridging science, strategy, and execution, NovaBridge enables transformative therapies to progress rapidly from discovery toward patients in need.

The Company’s differentiated pipeline is led by givastomig, a potential best-in-class, Claudin 18.2 x 4-1BB bispecific antibody, and VIS-101, a potential best-in-class bifunctional biologic, targeting VEGF-A and ANG2.

Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. The product candidate is being evaluated in a global, randomized Phase 2 study, following the recent announcement of positive topline results from a Phase 1b, multi-center, open label study in first line gastric cancer. The Company is also collaborating with its partner, ABL Bio, for the development of ragistomig, a bispecific antibody integrating PD-L1 as a tumor engager and 4-1BB as a conditional T cell activator, in solid tumors. Additionally, NovaBridge owns worldwide rights outside of China to uliledlimab, an anti-CD73 antibody that targets adenosine-driven immunosuppression in cancer.

VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration and diabetic macular edema. VIS-101 is currently completing a randomized, dose-ranging Phase 2a study for wet AMD. NovaBridge is the majority shareholder of Visara, Inc., and Visara controls global rights to VIS-101, outside of Greater China and certain countries in Asia.

For more information, please visit www.novabridge.com and follow us on LinkedIn.

NovaBridge Investor & Media Contacts

PJ Kelleher
LifeSci Advisors
+1-617-430-7579
pkelleher@lifesciadvisors.com

NovaBridge Biosciences
+1-240-745-6330
IR@novabridge.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will NovaBridge (NBP) present at the Leerink Partners 2026 Global Healthcare Conference?

NovaBridge will present on Wednesday, March 11, 2026 at 8:00 AM ET. According to the company, the appearance is a fireside chat during the conference running March 8-11, 2026 and is part of the scheduled program.

How can investors watch NovaBridge (NBP) at the Leerink Partners 2026 conference?

Investors can watch a live webcast of NovaBridge's presentation via the company's website. According to the company, the webcast link is on the News & Events page and will remain accessible for 90 days after the event.

What format is NovaBridge's (NBP) session at the Leerink Partners 2026 Global Healthcare Conference?

NovaBridge's session will be presented as a fireside chat at the conference. According to the company, the fireside chat format features management discussing recent developments and investor topics on March 11, 2026.

Will NovaBridge (NBP) make the Leerink Partners 2026 presentation available after the event?

Yes, the webcast will be available for replay on the company's website for 90 days. According to the company, the replay is accessible via the News & Events page for viewing after March 11, 2026.

Where can I find the NovaBridge (NBP) webcast link for the March 11, 2026 presentation?

The webcast link is posted on NovaBridge's News & Events webpage. According to the company, attendees and investors can access the link there and view the presentation live or via replay for 90 days.